Alivus Life — Q4 FY25 earnings call

Call held 16 May 2025

Management summary

Alivus Life delivered a robust Q4 performance characterized by strong revenue growth and significant margin expansion, driven by a favorable product mix and new launches. While the US market faces pricing erosion of 4-4.5%, management expects mid-teens volume growth to drive high single-digit revenue growth in FY26. The company is entering a heavy investment phase with a substantial capex plan for FY26, while maintaining a net debt-free balance sheet.

Highlights

  • Q4 Revenue reached ₹650 crores, representing a strong 21.1% YoY growth and 1.2% QoQ growth.

  • EBITDA margin for Q4 expanded significantly to 32.1%, up 520 bps YoY and 80 bps QoQ.

  • Full-year FY25 revenue stood at ₹2,387 crores, a 4.5% YoY growth (7.1% normalized for PLI impact).

  • PAT for Q4 was ₹142 crores with a margin of 21.8%; FY25 PAT was ₹486 crores (20.3% margin).

  • Volume growth for FY25 was 10%, with management guiding for mid-teens (~15%) growth in FY26.

  • Aggressive FY26 Capex guidance of ₹550-600 crores to fund Greenfield and Brownfield expansions.

  • CDMO segment showed recovery with 22.6% YoY growth in Q4, despite a soft full year due to cyclicality.

  • Working capital increased to 192 days, primarily due to a ₹200 crore bump in receivables from Glenmark (GPL) following a credit day extension to 150+ days.

Concerns

  • US Pricing Erosion

Key financials

  1. Revenue ₹650 Cr +21.1%YoY
  2. EBITDA Margin 32.1%
  3. PAT ₹142 Cr
  4. Gross Margin 56.5%
  5. R&D Expenditure ₹24 Cr
  6. Volume Growth 10% +10%YoY

What they filed

Q1 FY27: revenue up 6.3%, net profit up 31.1% against the same quarter last year.

₹ Cr · quarterly
Line itemQ2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26Q1 FY27
Revenue507 642 650 602 588 +16%673 +5%689 +6%640 +6%
EBITDA134 190 198 172 179 +34%231 +22%215 +9%212 +23%
Net profit95 137 142 122 130 +37%150 +9%163 +15%160 +31%
How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Segment breakdown

  • Generic Business
    22.6% Revenue Growth (Q4)
  • CDMO Business
    22.6% Revenue Growth (Q4)
  • GPL Business
    31% Revenue Growth (Q4)8.8% Revenue Growth (FY25)
  • Non-GPL Business
    19% Revenue Growth (Q4)6.3% Revenue Growth (FY25)

Guidance & targets

Volume

  • Volume Growth Volume · FY26 · High confidence mid-teens (~15%)

    Previously 10% → mid-teens (~15%)

    Looking ahead at FY’26 we expect volume growth in mid-teens.

    — Dr. Yasir Rawjee, MD & CEO

Revenue

  • Revenue Growth Revenue · FY26 · Medium confidence high single digits

    From 4.5% today

    However, given the pricing pressure we expect the revenue growth to be in the high single digits as it stands.

    — Dr. Yasir Rawjee, MD & CEO

Margin

  • EBITDA Margin Band Margin · foreseeable future · High confidence 28% to 30%

    From 30% today

    We would like to reiterate that margins will continue to be in the 28% to 30% band in the foreseeable future.

    — Dr. Yasir Rawjee, MD & CEO

Capex

  • Capital Expenditure Capex · FY26 · High confidence ₹550-600 crores

    Previously ₹166 crores → ₹550-600 crores

    No, it will be upwards of Rs.550. So you add Rs.190 to Rs.350, Rs.400 so we are around Rs.550-ish crores, Rs.550 to Rs.600.

    — Dr. Yasir Rawjee, MD & CEO

Capacity

  • 2650 KL Capacity Line Capacity · FY28 · Medium confidence FY28

    Previously FY27 → FY28

    Also, it seems we have pushed out 2650 KL capacity line from FY’27 to FY’28... while we thought we would need around 2600 KL by FY’27 we feel now that we can push it out.

    — Ahmed Madha (Analyst) / Yasir Rawjee

Risks & concerns

  • US Pricing Erosion

    high

    Management expects 4% to 4.5% pricing erosion on their portfolio, particularly on newer molecules.

    Both acknowledged

  • Working Capital / GPL Receivables

    medium

    Credit days for Glenmark (GPL) have increased to 150+ days, leading to a ₹200 crore bump in receivables.

    Analyst acknowledged

  • US Tariffs

    medium

    Potential impact of US tariffs on pharmaceutical supply chains; management notes industry lobbying against them.

    Analyst acknowledged

  • CDMO Cyclicality

    low

    CDMO performance was soft during the year due to the cyclical nature of demand and customer destocking.

    Management acknowledged

Areas of evasion (1)

  • Specific product-level details (e.g., Iron Sucrose) were deflected as 'under review'.

Q&A highlights

3 direct
Capacity Expansion and Capex Push-out Direct
The reason for that is that, we have done a lot more brownfield expansion especially on pharma capacity, both in Dahej as well as Ankleshwar which will be completed this year. So given that kind of pharma capacity, we will have a pretty good runway for the next couple maybe even two, three years.

Explains the strategic shift from rapid greenfield volume expansion to utilizing brownfield capacity, impacting near-term capex and asset turnover.

Asked by Ahmed Madha

US Pricing Erosion vs. Volume Growth Direct
See typical Nitesh we see about 4% to 4.5% of erosion on our pipeline... we are already seeing a volume growth of mid-teens that is very clear... depending on how we are able to manage that erosion, we should be definitely in the high single digits to be able to drive the growth.

Clarifies the disconnect between strong volume growth and more modest revenue growth expectations due to competitive pricing pressure in the US.

Asked by Nitesh Dutt

GPL Receivables and Credit Days Direct
Glenmark Pharma has the increased number of days as per the agreement. So the entire Rs.200 crores that you see as a bump up is all on account of that... that will be upwards of 150 days as per the agreement.

Highlights a significant working capital headwind and potential cash flow impact resulting from the relationship with the former parent company.

Asked by Ahmed Madha

2 min read 5 chapters

Detailed narrative

Robust Q4 Performance and FY25 Summary

Alivus Life concluded FY25 with a strong Q4, reporting revenue of ₹650 crores, a 21.1% YoY increase. EBITDA margins for the quarter reached a high of 32.1%, driven by a favorable product mix and successful new launches in ROW markets. For the full year, the company achieved ₹2,387 crores in revenue, meeting its 4.5% growth guidance despite the absence of PLI benefits. The therapeutic mix remains dominated by CVS and CNS, which together contribute 55% of the top line.

Strategic Capex and Capacity Expansion

The company is embarking on an aggressive investment phase, guiding for ₹550-600 crores in capex for FY26. This includes ₹190 crores carried over from FY25 and ₹350-400 crores in new approvals for Greenfield expansion in Solapur, Brownfield expansion in Ankleshwar and Dahej, and a new R&D center near Mumbai (budgeted at ₹70-80 crores). Management has strategically pushed out the 2650 KL capacity line to FY28, opting to prioritize brownfield pharma capacity that will be completed this year.

US Market Dynamics: Navigating Pricing Erosion

The US market, which accounts for 25-30% of total business, is experiencing pricing erosion of approximately 4% to 4.5%, particularly on newer molecules. Despite this, management is confident in achieving mid-teens volume growth (~15%) in FY26, which they expect will translate into high single-digit revenue growth. The company also noted that the Ankleshwar plant received its EIR following a US FDA inspection in January 2025, reinforcing its regulatory standing.

CDMO Segment: Recovery and Pipeline Progress

After a soft year due to cyclical demand and customer destocking, the CDMO business showed signs of recovery with 22.6% growth in Q4. The segment currently relies on three commercial products, with a fourth project gaining traction and a fifth Japanese innovator project expected to commercialize in H2 FY26. Management targets scaling the CDMO business significantly by FY28, though they acknowledged that reaching 4x the FY24 size by then might be challenging.

Working Capital and the Glenmark (GPL) Relationship

Working capital days increased to 192 in FY25, largely due to a ₹200 crore increase in receivables from Glenmark Pharma (GPL). Under a new agreement, credit days for GPL have been extended to upwards of 150 days. While this impacts cash conversion, management maintains that the non-GPL business remains steady and the company continues to be net debt-free with ₹549 crores in cash and short-term investments.

This is an AI-generated summary of a publicly available earnings call transcript.
View original transcript

More Healthcare earnings calls